These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37568223)

  • 1. Risk of dementia in primary aldosteronism compared with essential hypertension: a nationwide cohort study.
    Hong N; Kim KJ; Yu MH; Jeong SH; Lee S; Lim JS; Rhee Y
    Alzheimers Res Ther; 2023 Aug; 15(1):136. PubMed ID: 37568223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-Dependent Risk of Atrial Fibrillation in Patients With Primary Aldosteronism After Medical or Surgical Treatment Initiation.
    Kim KJ; Hong N; Yu MH; Lee H; Lee S; Lim JS; Rhee Y
    Hypertension; 2021 Jun; 77(6):1964-1973. PubMed ID: 33866798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of Different Treatment Strategies on New-Onset Atrial Fibrillation Among Patients With Primary Aldosteronism: A Nationwide Longitudinal Cohort-Based Study.
    Pan CT; Liao CW; Tsai CH; Chen ZW; Chen L; Hung CS; Liu YC; Lin PC; Chang CC; Chang YY; Wu VC; Lin YH;
    J Am Heart Assoc; 2020 Mar; 9(5):e013699. PubMed ID: 32070205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments.
    Wu VC; Wang SM; Huang KH; Tsai YC; Chan CK; Yang SY; Lin LY; Chang CC; Lu CC; Lin YH; Chen YM; Chueh JS
    Eur J Endocrinol; 2021 Dec; 186(2):195-205. PubMed ID: 34851859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of sepsis in patients with primary aldosteronism.
    Chan CK; Hu YH; Chen L; Chang CC; Lin YF; Lai TS; Huang KH; Lin YH; Wu VC; Wu KD;
    Crit Care; 2018 Nov; 22(1):313. PubMed ID: 30463626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism.
    Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
    JAMA Cardiol; 2018 Aug; 3(8):768-774. PubMed ID: 30027227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Fracture in Primary Aldosteronism: A Population-Based Cohort Study.
    Wu VC; Chang CH; Wang CY; Lin YH; Kao TW; Lin PC; Chu TS; Chang YS; Chen L; Wu KD; Chueh SJ
    J Bone Miner Res; 2017 Apr; 32(4):743-752. PubMed ID: 27862274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life in primary aldosteronism: A prospective observational study.
    Buffolo F; Cavaglià G; Burrello J; Amongero M; Tetti M; Pecori A; Sconfienza E; Veglio F; Mulatero P; Monticone S
    Eur J Clin Invest; 2021 Mar; 51(3):e13419. PubMed ID: 32997795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism.
    Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
    Hypertension; 2018 Sep; 72(3):658-666. PubMed ID: 29987110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of new-onset autoimmune diseases in primary aldosteronism: a nation-wide population-based study.
    Er LK; Chen L; Tsai YC; Lin YH; Huang WC; Chang CC; Lu CC; Huang KH; Chueh JS; Wu KD; Wu VC;
    J Hypertens; 2020 Apr; 38(4):745-754. PubMed ID: 31764584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry.
    Parra Ramírez P; Martín Rojas-Marcos P; Paja Fano M; González-Boillos M; Pascual-Corrales E; García Cano AM; Ruiz-Sanchez JG; Vicente Delgado A; Gómez Hoyos E; Ferreira R; García Sanz I; Recasens Sala M; Barahona San Millan R; Picón César MJ; Díaz Guardiola P; Perdomo CM; Manjón-Miguélez L; Rebollo Román Á; Robles Lázaro C; Morales-Ruiz M; Calatayud M; Andree Furio Collao S; Meneses D; Sampedro-Nuñez MA; Mena Ribas E; Sanmartín Sánchez A; Gonzalvo Diaz C; Lamas C; Guerrero-Vázquez R; Del Castillo Tous M; Serrano Gotarredona J; Michalopoulou Alevras T; Tenés Rodrigo S; Roa Chamorro R; Jaen Aguila F; Moya Mateo EM; Hanzu FA; Araujo-Castro M
    High Blood Press Cardiovasc Prev; 2024 Jan; 31(1):43-53. PubMed ID: 38225508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.
    Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
    Lancet Diabetes Endocrinol; 2018 Jan; 6(1):51-59. PubMed ID: 29129576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study.
    Fernández-Argüeso M; Pascual-Corrales E; Bengoa Rojano N; García Cano A; Jiménez Mendiguchía L; Araujo-Castro M
    Endocrine; 2021 Aug; 73(2):439-446. PubMed ID: 33797699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality in Patients With Primary Aldosteronism: A Swedish Nationwide Study.
    Gkaniatsa E; Zverkova Sandström T; Rosengren A; Trimpou P; Olsson DS; Lind M; Muth A; Johannsson G; Ragnarsson O
    Hypertension; 2023 Dec; 80(12):2601-2610. PubMed ID: 37855142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Plasma Concentrations of ACE2 in Primary Aldosteronism and Cardiovascular Outcomes.
    Wu VC; Peng KY; Hu YH; Chang CC; Chan CK; Lai TS; Lin YH; Wang SM; Lu CC; Liu YC; Tsai YC; Chueh JS
    J Clin Endocrinol Metab; 2022 Nov; 107(12):3242-3251. PubMed ID: 36125178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment.
    Turchi F; Ronconi V; di Tizio V; Ceccoli L; Boscaro M; Giacchetti G
    Nutr Metab Cardiovasc Dis; 2014 May; 24(5):476-82. PubMed ID: 24630976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial Fibrillation in Primary Aldosteronism.
    Pan CT; Tsai CH; Chen ZW; Chang YY; Wu VC; Hung CS; Lin YH;
    Horm Metab Res; 2020 Jun; 52(6):357-365. PubMed ID: 32289838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular events and all-cause mortality in surgically or medically treated primary aldosteronism: A Meta-analysis.
    Jing Y; Liao K; Li R; Yang S; Song Y; He W; Wang K; Yang J; Li Q; Hu J
    J Renin Angiotensin Aldosterone Syst; 2021; 22(1):14703203211003781. PubMed ID: 33752505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations Between Metabolic Profiles and Target-Organ Damage in Chinese Individuals With Primary Aldosteronism.
    Zhang SL; Gao JW; Guo Y; Feng QL; Tang JY; Yan L; Wang JF; Cheng H; Liu PM
    Front Endocrinol (Lausanne); 2020; 11():547356. PubMed ID: 33101195
    [No Abstract]   [Full Text] [Related]  

  • 20. Risky business: a single-centre cross-sectional analysis of calculated cardiovascular risk in patients with primary aldosteronism and essential hypertension.
    Solanki P; Gwini SM; Libianto R; Gabb G; Shen J; Young MJ; Fuller PJ; Yang J
    BMJ Open; 2022 Nov; 12(11):e062406. PubMed ID: 36375972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.